Cumulative isotretinoin dose, the total amount taken across a course of this acne drug, showed no extra benefit at 150 mg/kg versus 120 mg/kg. The Limbic reports 12-month relapse rates of 26.7% for 120 mg/kg and 32.3% for 150 mg/kg, so the higher total did not prevent more relapses The Limbic trial summary.
The trial enrolled 91 adolescents and young adults with moderate-to-severe cystic acne. It tracked lesion counts during treatment and acne return during 12 months after finishing. For adults with persistent acne, the message is practical: pushing past the conventional total did not buy lasting clearance.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the 120 versus 150 trial tested
- Why adults with persistent acne should pay attention
- Does a higher total ever lower relapse?
- How to plan dosing with your clinician
What the 120 versus 150 trial tested
The Veeva registry describes a single-center randomized single-blind controlled trial started in 2001. It compared 120 versus 150 mg/kg by body weight and clinical response. The two groups received fixed low daily dosing and follow-up for one year.
Lesion counts fell in both groups, but relapse stayed common. No advantage appeared for the higher cumulative total. The comparison was small and narrow. A Muck Rack summary of the 2026 correspondence notes single-center enrollment, fixed 10-20 mg/day dosing without accounting for treatment duration, and a young population rather than only adults with persistent acne.
Why adults with persistent acne should pay attention
Relapse after isotretinoin remains common in larger practice. The JAMA Dermatology cohort described in PMC followed 19,907 patients, with 22.5% having acne relapse and 8.2% having isotretinoin retrial PMC cohort record. Adult women are a key affected group. The U.S.
National Library of Medicine PubMed record for the 2025 Lai/Barbieri study lists higher relapse risk for female patients, with hazard ratio 1.43, but lower retrial rates, with hazard ratio 0.68. That pattern matters for persistent adult acne. Recurrence risk is real, yet decisions about retreatment involve scarring, severity, prior response, and medical history. The 120-versus-150 trial alone cannot set adult care.
Does a higher total ever lower relapse?
A larger dose-response picture is more graded. Medical Xpress, reporting the Mass General/JAMA Dermatology analysis, found each added mg/kg lowered relapse risk with hazard ratio 0.996 and retrial risk with hazard ratio about 0.99, with benefit plateauing beyond about 220 mg/kg. Daily intensity is a separate question.
DermSquared, reporting the same JAMA Dermatology work, found that among patients reaching 120-220 mg/kg or higher, a higher maximum daily dose did not further lower relapse or retrial risk. Together, the findings point to total exposure rather than daily push. Once a conventional total is reached, raising the daily dose did not add prevention.
How to plan dosing with your clinician
U.S. labeling supports planning by total rather than by daily escalation.
FDA DailyMed isotretinoin information recommends 0.5-1 mg/kg/day in divided doses for 15-20 weeks and advises waiting at least 2 months before a second course FDA DailyMed labeling. Bring these points to the visit: Do not extend or repeat isotretinoin on your own to chase a higher total. Ask your clinician whether your history, severity, and prior response support the standard cumulative target, a longer observation period, or a different next step.
- confirm weight-based target range and treatment length for the first course
- ask how response, tolerability, and labs affect dose changes
- clarify what counts as relapse and when retreatment would be considered
- confirm the required wait before any second course
You Might Also Like
- Concurrent Acne Procedures and Isotretinoin in 2026 Research: What the Findings Mean for Adults With Persistent Acne
- Topical Clascoterone Evidence Revisited in 2026: What the Findings Mean for Adults With Persistent Acne
- The 2026 Review of Topical Antibiotic Monotherapy for Acne: Questions Adults With Persistent Acne Can Ask a Dermatologist